Our group pioneered the study of SGO1 in breast cancer in general by demonstrating, using cBIOPORTAL, that the overexpression of SGO1 in breast tumors correlates with the overexpression of the E2F transcriptional activators E2F1, E2F2, and E2F3 [23]. This evidence concerns the gene E2F3 and breast carcinoma.